Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 2, 2011, Pages 273-284

  Stein, Rhona ^a   Balkman, Cheryl ^b   Chen, Susan ^a   Rassnick, Kenneth ^b   McEntee, Margaret ^b   Page, Rodney ^c   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

dog; HLA DR; IMMU 114; L243; lymphoma; Monoclonal antibody

Indexed keywords

ASPARAGINASE; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMMU 114; MONOCLONAL ANTIBODY L243; PREDNISONE; PROCARBAZINE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DOG; DRUG BINDING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; LYMPHOCYTE; LYMPHOCYTOPENIA; LYMPHOMA; LYMPHOMA CELL; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NEUTROPHILIA; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WEAKNESS;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; DOGS; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; LYMPHOMA, B-CELL; PILOT PROJECTS;

EID: 79551616720     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.535182     Document Type: Article

References (31)

1. Dewhirst MW, Thrall DE, MacEwen EG. Spontaneous pet animal cancers. In: Teicher BA, editor. Tumor models in cancer research. Totowa, NJ: Humana Press; 2001. pp 565- 589.
2. Hansen K, Khanna C. Spontaneous and genetically engineered animal models: use in preclinical cancer drug development. Eur J Cancer 2004;40:858-880.
3. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008;8:147-156.
4. Vail DM, Young KM. Canine lymphoma and lymphoid leukemia. In: Withrow SJ, Vail DM, editors. Small animal clinical oncology. 4th ed. St. Louis, MO: Saunders; 2007. pp 699-733.
5. Modiano JF, Breen M, Burnett RC, et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res 2005;65:5654-5661.
6. Breen M, Modiano JF. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans - man and his best friend share more than companionship. Chromosome Res 2008;16:145-154.
7. Brown KS, Levitt DJ, Shannon M, Link BK. Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma. Clin Lymphoma 2001;2:188-190.
8. DeNardo GL, Tobin E, Chan K, Bradt BM, DeNardo SJ. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLADR antibodies and 90Y-labeled HLA-DR antibodies. Clin Cancer Res 2005;11:7075s-7079s.
9. Stein R, Qu Z, Chen S, Solis D, Hansen HJ, Goldenberg DM. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood 2006;108:2736-2744.
10. Stein R, Gupta P, Cardillo TM, et al. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyper-activation of ERK and JNK MAP kinase signaling pathways. Blood 2010;115:5180-5190.
11. Dechant M, Bruenke J, Valerius T. HLA class II antibodies in the treatment of hematologic malignancies. Semin Oncol 2003;30:465-475.
12. Shi JD, Bullock C, Hall WC, et al. In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLADR expressed on B cells. Leuk Lymphoma 2002;43:1303-1312.
13. Rech J, Repp R, Rech D, et al. A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study. Leuk Lymphoma 2006;47:2147-2154.
14. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the sideeffects of rituximab treatment. Br J Haematol 2001;115:807-811.
15. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU- 106, and its use in combination with the humanized anti- CD22 antibody, epratuzumab, for the therapy of non- Hodgkin's lymphoma. Clin Cancer Res 2004;10:2868-2878.
16. Veterinary co-operative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195-213.
17. Henricsson A, Bergentz SE. Role of platelets and lymphocytes for the hemodynamic effects of rapidly injected antilymphocyte globulin. Eur Surg Res 1978;10:40-49.
18. Mathews KA, Gallivan GJ, Mallard BA. Clinical, biochemical and hematologic evaluation of normal dogs after administrationof rabbit anti-dog thymocyte serum. Vet Surg 1993; 22:213-220.
19. Nagy ZA, Mooney NA. A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules. J Mol Med 2003;81:757-765.
20. Mone AP, Huang P, Pelicano H, et al. Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood 2004;103:1846-1854.
21. Newell MK, VanderWall J, Beard KS, Freed JH. Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. Proc Natl Acad Sci USA 1993;90:10459-10463.
22. Truman JP, Choqueux C, Tschopp J, et al. HLA class IImediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes. Blood 1997;89:1996-2007.
23. Altomonte M, Visintin A, Tecce R, et al. Targeting of HLADR molecules transduces agonistic functional signals in cutaneous melanoma. J Cell Physiol 2004;200:272-276.
24. Aoudjit F, Guo W, Gagnon-Houde JV, et al. HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells. Exp Cell Res 2004;299:79-90.
25. Fernández EM, O'Toole PJ, Morrison IE, Cherry RJ, Fernández N. Interaction of HLA-DR with actin microfilaments. Hum Immunol 2003;64:327-337.
26. Guo W, Mourad W, Charron D, Al-Daccak R. Ligation of MHC class II molecules differentially upregulates TNF beta gene expression in B cell lines of different MHC class II haplotypes. Hum Immunol 1999;60:312-322.
27. Coral S, PucilloC, Leonardi A, Fonsatti E, Altomonte M, Maio M. Triggering of HLA-DR antigens differentially modulates tumor necrosis factor alpha release by B cells at distinct stage of maturation. Cell Growth Differ 1997;8:581-588.
28. Mourad W, Geha RS, Chatila T. Engagement of major histocompatibility complex class II molecules induces sustained, lymphocyte function-associated molecule 1-dependent cell adhesion. J Exp Med 1990;172:1513-1516.
29. Blancheteau V, Charron D, Mooney N. HLA class II signals sensitize B lymphocytes to apoptosis via Fas/CD95 by increasing FADD recruitment to activated Fas and activation of caspases. Hum Immunol 2002;63:375-383.
30. Elasser D, Valerius T, Repp R, et al. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 1996;87:3803-3812.
31. Kabelitz D, Janssen O. Growth inhibition of Epstein- Barr irus transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down regulation of CD23 antigen expression. Cell Immunol 1989;120:21-30.